## Highlights of This Issue

### SPECIAL FEATURES

#### CCR Translations

**6645**  
The Context of Blood Vessels and Response to VEGF-Targeted Therapy  
Brian I. Rini  
*See related article, p. 6943*

#### CCR Perspectives in Drug Approval

**6650**  
Abiraterone Acetate in Combination with Prednisone for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer: U.S. Food and Drug Administration Drug Approval Summary  

#### CCR Drug Updates

**6657**  
Pralatrexate Pharmacology and Clinical Development  
Enrica Marchi, Michael Mangone, Kelly Zullo, and Owen A. O’Connor

#### Molecular Pathways

**6662**  
Molecular Pathways: Targeting MALT1 Paracaspase Activity in Lymphoma  
Lorena Fontán and Ari Melnick

#### Perspectives

**6669**  
Anticipating the Clinical Use of Prognostic Gene Expression-Based Tests for Colon Cancer Stage II and III: Is Godot Finally Arriving?  
Anita Sveen, Arild Nesbakken, Trude H. Aagesen, Marianne G. Guren, Kjell M. Tveit, Rolf S. Skotheim, and Ragnhild A. Lothe

### Review

**6647**  
A review of Hepatocellular Carcinoma from an Immunologic Perspective  
Tim F. Greten, Austin G. Duffy, and Firouzeh Korangy

### HUMAN CANCER BIOLOGY

**6668**  
Poor Concordance among Nine Immunohistochemistry Classifiers of Cell-of-Origin for Diffuse Large B-Cell Lymphoma: Implications for Therapeutic Strategies  
Rita Coutinho, Andrew James Clear, Andrew Owen, Andrew Wilson, Janet Matthews, Abigail Lee, Rute Alvarez, Maria Gomes da Silva, José Cabeças, Maria Camahirina, and John G. Gribben

**6669**  
BRAF Fusions Define a Distinct Molecular Subset of Melanomas with Potential Sensitivity to MEK Inhibition  

**6678**  
HAb18G/CD147 Promotes pSTAT3-Mediated Pancreatic Cancer Development via CD44s  
Ling Li, Wenhua Tang, Xiaoting Meng, Rachel Thompson, Xinbao Hao, Yongmin Li, Xiaotan T. Qiao, Jiayuh Lin, James Fuchs, Diane M. Simeone, Zhi-Nan Chen, Theodore S. Lawrence, and Liang Xu

### CANCER THERAPY: PRECLINICAL

**6716**  
Development, Characterization, and Reversal of Acquired Resistance to the MEK1 Inhibitor Selumetinib (AZD6244) in an In Vivo Model of Childhood Astrocytoma  
Hemant K. Bid, Aaron Kibler, Doris A. Phelps, Sagaympek Manap, Lirinlin Xiao, Jiayuh Lin, David Capper, Duane Oswald, Brian Geier, Mariko DeWire, Paul D. Smith, Raushan T. Kurmasheva, Xiaokui Mo, Soledad Fernandez, and Peter J. Houghton
Ang-2-VEGF-A CrossMab, a Novel Bispecific Human IgG1 Antibody Blocking VEGF-A and Ang-2 Functions Simultaneously, Mediates Potent Antitumor, Antiangiogenic, and Antimetastatic Efficacy

Yvonne Kienast, Christian Klein, Werner Scheurer, Romi Raemisch, Erica Lorenzon, Dirk Bernicke, Frank Herting, Sidney Yu, Huynh Hung The, Laurent Martarelo, Christian Gassner, Kay-Gunnar Stubenrauch, Kate Munro, Hellmut G. Augustin, and Markus Thomas

Reprogramming Metabolism with Metformin Improves Tumor Oxygenation and Radiotherapy Response

Vanessa E. Zannella, Alan Dal Pra, Hala Muaddi, Trevor D. McKee, Shawn Stapleton, Jenna Sykes, Rachel Glicksman, Selim Chaib, Paul Zamiara, Michael Milesevic, Bradly G. Wouters, Robert G. Bristow, and Marianne Koritzinsky

Increased TGF-α as a Mechanism of Acquired Resistance to the Anti-EGFR Inhibitor Cetuximab through EGFR–MET Interaction and Activation of MET Signaling in Colon Cancer Cells

Teresa Troiani, Erika Martinelli, Stefania Napolitano, Donata Vitagliano, Loretta Pia Ciuffreda, Sara Costantino, Floriana Morgillo, Anna Capasso, Vincenzo Sforza, Anna Nappi, Raffaele De Palma, Elena D’Altimari, Liberato Berrino, Roberto Bianco, and Fortunato Ciardiello

Use of the Proton Pump Inhibitor Pantoprazole to Modify the Distribution and Activity of Doxorubicin: A Potential Strategy to Improve the Therapy of Solid Tumors

Krupa J. Patel, Carol Lee, Qian Tan, and Ian F. Tannock

The Janus Kinases Inhibitor AZD1480 Attenuates Growth of Small Cell Lung Cancers In Vitro and In Vivo

Jih-Hsiang Lee, Kang-Seo Park, Anna Teresa Alberobello, Bhaskar Kallakury, Meng-Tzu Weng, Yisong Wang, and Giuseppe Giaccone

A Personalized Preclinical Model to Evaluate the Metastatic Potential of Patient-Derived Colon Cancer Initiating Cells

Isabel Puig, Irene Chicote, Stephanie P. Tenbaum, Oriol Arquès, Jose Raúl Herance, Juan D. Gispert, Jose Jimenez, Stefania Landolfi, Karina Caci, Helena Allende, Leire Mendizabal, Debora Moreno, Ramón Charco, Eloy Espin, Aleix Prat, Maria Elena Elez, Guillem Argilés, Ana Vivancos, Josep Tabernero, Santiago Rojas, and Héctor G. Palmer

Monoclonal Antibody against Cell Surface GRP78 as a Novel Agent in Suppressing P13K/AKT Signaling, Tumor Growth, and Metastasis

Ren Liu, Xiuqing Li, Wenhong Guo, Yue Zhou, Shuan Wey, Satyajit K. Mitra, Valery Krasnoperov, Dezhe Dong, Shuanglei Liu, Dan Li, Genyuan Zhu, Stan Louie, Peter S. Conti, Zibo Li, Amy S. Lee, and Parkash S. Gill

IMAGING, DIAGNOSIS, PROGNOSIS

Prognostic Significance of Pretreatment Serum Cytokines in Classical Hodgkin Lymphoma


A Novel Engineered Anti-CD20 Tracer Enables Early Time PET Imaging in a Humanized Transgenic Mouse Model of B-cell Non-Hodgkins Lymphoma

Arutzelvan Natarajan, Benjamin J. Hackel, and Sanjiv Sam Gambhir

Loss of PTEN Expression Is Associated with Poor Prognosis in Patients with Intraductal Papillary Mucinous Neoplasms of the Pancreas


Epigenetic Inactivation of microRNA-34b/c Predicts Poor Disease-Free Survival in Early-Stage Lung Adenocarcinoma

The Residual Tumor Autophagy Marker LC3B Serves as a Prognostic Marker in Local Advanced Breast Cancer after Neoadjuvant Chemotherapy

Sheng Chen, Yi-Zhou Jiang, Liang Huang, Ruo-Ji Zhou, Ke-Da Yu, Yin Liu, and Zhi-Ming Shao

CANCER THERAPY: CLINICAL

Comparative Efficacy of Bisphosphonates in Metastatic Breast and Prostate Cancer and Multiple Myeloma: A Mixed-Treatment Meta-analysis

Carlo Palmieri, John R. Fullarton, and Janet Brown

Cladribine with Immediate Rituximab for the Treatment of Patients with Variant Hairy Cell Leukemia

Robert J. Kreitman, Wyndham Wilson, Katherine R. Calvo, Evgeny Arons, Laura Roth, Jeffrey Sapolsky, Hong Zhou, Mark Raffeld, and Maryalice Stetler-Stevenson

Phase I Study of Panobinostat plus Everolimus in Patients with Relapsed or Refractory Lymphoma

Yasuhiro Oki, Daniela Buglio, Michelle Fanale, Luis Fayad, Amanda Copeland, Jorge Romaguera, Larry W. Kwaak, Barbara Pro, Silvana de Castro Faria, Sattva Neelapu, Nathan Fowler, Fredrick Hagemeister, Jie Xin Zhang, Shouhao Zhou, Lei Feng, and Anas Younes

Long-term Survival and Biomarker Correlates of Tasquinimod Efficacy in a Multicenter Randomized Study of Men with Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer


Phase I Trial of Preoperative Chemoradiation plus Sorafenib for High-Risk Extremity Soft Tissue Sarcomas with Dynamic Contrast-Enhanced MRI Correlates


PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE

Loss of NAPRT1 Expression by Tumor-Specific Promoter Methylation Provides a Novel Predictive Biomarker for NAMPT Inhibitors

David S. Shames, Kristi Elkins, Kimberly Walter, Thomas Holcomb, Pan Du, Dane Mohl, Yang Xiao, Thinh Pham, Peter M. Havery, Bianca Liederer, Xiaorong Liang, Robert L. Yauh, Thomas O’Brien, Richard Bourgon, Hartmut Koeppe, and Lisa D. Belmont

The Effect of VEGF-Targeted Therapy on Biomarker Expression in Sequential Tissue from Patients with Metastatic Clear Cell Renal Cancer


Large-scale Analysis of PDGFRA Mutations in Melanomas and Evaluation of Their Sensitivity to Tyrosine Kinase Inhibitors Imatinib and Crenolanib

Jie Dai, Yan Kong, Lu Li, Zhihong Chi, Chuanliang Cui, Xuan Sheng, Lili Mao, Siming Li, Bin Lian, Ruirong Yang, Shujing Liu, Xiaowei Xu, and Jun Guo

Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy


See related article, p. 6647

Prognostic and Predictive Blood-Based Biomarkers in Patients with Advanced Pancreatic Cancer: Results from CALGB80303 (Alliance)

Andrew B. Nixon, Herbert Pang, Mark D. Starr, Paula N. Friedman, Monica M. Bertagnolli, Hedy L. Kindler, Richard M. Goldberg, Alan P. Venook, and Herbert I. Hurwitz for the Alliance for Clinical Trials In Oncology
Comprehensive Biomarker Analysis and Final Efficacy Results of Sorafenib in the BATTLE Trial

Evaluation and Clinical Analyses of Downstream Targets of the Akt Inhibitor GDC-0068
Yibing Yan, Violeta Serra, Ludmila Prudkin, Maurizio Scaltriti, Sumati Murli, Olga Rodriguez, Marta Guzman, Deepak Sampath, Michelle Nannini, Yuanyuan Xiao, Marie-Claire Wagle, Jenny Q. Wu, Matthew Wongchenko, Garret Hampton, Vanitha Ramakrishnan, Mark R. Lackner, Cristina Saura, Desamparados Roda, Andres Cervantes, Josep Tabernero, Premal Patel, and Jose Baselga

Acknowledgment to Reviewers

ABOUT THE COVER
The cover shows drug distribution in a solid tumor derived from breast cancer cells in a mouse xenograft. Immunohistochemical staining shows enhanced doxorubicin distribution around functional blood vessels in mice pretreated with pantoprazole. For details, see the article by Patel and colleagues on page 6766 of this issue.
Clinical Cancer Research

19 (24)


Updated version 
Access the most recent version of this article at:  
http://clincancerres.aacrjournals.org/content/19/24

E-mail alerts 
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions 
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions 
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.